Recruiting
Phase 1
Phase 2

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Sponsor:

CRISPR Therapeutics AG

Code:

NCT05565248

Conditions

Diabetes Mellitus

Diabetes Mellitus, Type 1

Glucose Metabolism Disorders

Metabolic Disease

Endocrine System Diseases

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

VCTX211

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information